吉林大学学报(医学版) ›› 2025, Vol. 51 ›› Issue (2): 392-402.doi: 10.13481/j.1671-587X.20250213

• 基础研究 • 上一篇    

CSPG4P12基因在小细胞肺癌组织中的表达及其对细胞生物学行为的影响

白聪聪1,周先雷2,张志3,高爽1,张雪梅1()   

  1. 1.华北理工大学生命科学学院细胞与分子科,河北 唐山 063210
    2.华北理工大学公共卫生学院流行病预防科,河北 唐山 063210
    3.华北理工大学附属唐山工人医院肿瘤内二科,河北 唐山 063000
  • 收稿日期:2024-04-19 接受日期:2024-06-11 出版日期:2025-03-28 发布日期:2025-04-22
  • 通讯作者: 张雪梅 E-mail:zhangxuemei@ncst.edu.cn
  • 作者简介:白聪聪(1998-),女,甘肃省庆阳市人,在读硕士研究生,主要从事恶性肿瘤病因以及分子靶向治疗方面的研究。
  • 基金资助:
    河北省科技厅自然科学基金重点项目(H2017209233);河北省教育厅高等学校科学技术研究项目(基础研究)(QN2021119)

Expression of CSPG4P12 gene in small cell lung cancer tissue and its effect on behaviors of cell biology

Congcong BAI1,Xianlei ZHOU2,Zhi ZHANG3,Shuang GAO1,Xuemei ZHANG1()   

  1. 1.Department of Cell and Molecular Biology,School of Life Sciences,North China University of Science and Technology,Tangshan 063210,China
    2.Department of Epidemic Prevention,School of Public Health,North China University of Science and Technology,Tangshan 063210,China
    3.Second Department of Oncology,Tangshan Workers Hospital,North China University of Science and Technology,Tangshan 063000,China
  • Received:2024-04-19 Accepted:2024-06-11 Online:2025-03-28 Published:2025-04-22
  • Contact: Xuemei ZHANG E-mail:zhangxuemei@ncst.edu.cn

摘要:

目的 探讨硫酸软骨素蛋白聚糖4假基因12(CSPG4P12)在小细胞肺癌(SCLC)组织中的表达、与免疫浸润的关系及其对细胞生物学功能的影响,阐明其在SCLC发生发展中的作用。 方法 通过ArrayExpress数据库检索获得的SCLC的E-GEOD-60052队列数据,利用R语言Bioconductor包完成数据过滤标准化,并获得63例SCLC肿瘤组织和7例正常组织样本,使用Mann-Whitney U检验分析2组样本中CSPG4P12表达水平差异情况,使用Pearson相关性分析评估CSPG4P12表达水平与47种免疫检查点基因之间的关联。使用ESTIMATE算法和CIBERSORT算法评估CSPG4P12表达与肿瘤免疫细胞浸润之间的关联。采用病例对照研究分析临床资料,选取230例SCLC患者为病例组,230名健康体检者为对照组。采用TaqMan-MGB荧光探针标记法进行CSPG4P12 rs2880765、rs6496932和rs8040855位点基因分型实验,通过非条件Logistic回归模型计算比值比(OR)和95%置信区间(CI),分析CSPG4P12基因多态遗传变异与SCLC发病风险的关联。SCLC DMS114细胞分别转染pUC-57质粒(对照组)和CSPG4P12过表达质粒(OV-CPG4P12组),采用实时荧光定量PCR(RT-qPCR)法验证2组细胞中CSPG4P12过表达效率。采用细胞计数试剂盒8(CCK-8)法检测2组细胞增殖活性,Transwell小室实验检测2组迁移细胞数和侵袭细胞数,Hoechst 33342荧光染色法观察2组细胞凋亡情况。 结果 ArrayExpress数据库E-GEOD-60052队列分析,与正常组织比较,SCLC肿瘤组织中CSPG4P12 mRNA表达水平明显降低(P<0.001)。CSPG4P12表达与免疫检查点基因白细胞相关免疫球蛋白样受体1(LAIR1)(r=0.47,P<0.001)、肿瘤坏死因子(TNF)受体超家族成员9(TNFRSF9)(r=0.38,P<0.01)和TNF超家族成员9(TNFSF9)(r=0.44,P<0.001)均呈正相关关系。ESTIMATE算法,CSPG4P12低表达组患者基质评分、免疫评分和ESTIMATE综合评分均低于CSPG4P12高表达组(P<0.01)。CIBERSORT算法,与CSPG4P12高表达组比较,CSPG4P12低表达组中M0型巨噬细胞浸润增加(P<0.05),静息肥大细胞浸润降低(P<0.05)。CSPG4P12表达水平与静息肥大细胞浸润(r=0.35,P=0.030)和单核细胞浸润(r=0.34,P=0.034)呈正相关关系。病例对照研究,与AA基因型比较,CSPG4P12 rs2880765位点AT和TT基因型携带者患SCLC风险增加(OR=1.68,95%CI=1.15~2.45,P<0.01)。分层分析,在男性、低年龄(≤60岁)及吸烟亚组人群中,rs2880765 A>T遗传变异可增加SCLC发病风险(男性:OR=1.86,95%CI=1.18~2.93,P<0.01;≤60岁:OR=1.73,95%CI=1.11~2.68,P<0.01;吸烟:OR=2.76,95%CI=1.49~5.13,P=0.001)。细胞生物学实验,与对照组比较,在48和72 h时,OV-CSPG4P12组细胞增殖活性明显降低(P<0.01);24 h时迁移细胞数明显减少(P<0.01),凋亡细胞数明显增加(P<0.05),48 h时侵袭细胞数明显减少(P<0.01)。 结论 CSPG4P12在SCLC肿瘤组织中低表达,与免疫浸润有关联。CSPG4P12 rs2880765 A>T遗传变异可以增加SCLC发病风险,其过表达能抑制细胞增殖、迁移和侵袭,促进细胞凋亡。

关键词: 硫酸软骨素蛋白多糖4假基因12, 免疫浸润, 遗传变异, 细胞生物学功能, 小细胞肺癌

Abstract:

Objective To investigate the expression of chondroitin sulfate proteoglycan 4 pseudogene 12 (CSPG4P12) in the small cell lung cancer (SCLC) tissue, its relationship with immune infiltration, and its effect on cell biological functions, and to clarify its effect in the occurrence and development of SCLC. Methods The E-GEOD-60052 cohort was obtained by searching the ArrayExpress database for SCLC. The R language Bioconductor package was used to complete data filtering standardization, and 63 samples of SCLC tumor tissues and 7 samples of normal tissues were obtained. The Mann-Whitney U test was used to analyze the difference in CSPG4P12 expression levels between two groups. Pearson correlation analysis was used to evaluate the associations between CSPG4P12 expression levels and 47 immune checkpoint genes. The ESTIMATE algorithm and CIBERSORT algorithm were used to evaluate the correlations between CSPG4P12 expression and tumor immune cell infiltration. A case-control study was used to analyze the clinical data. A total of 230 patients with SCLC were selected as case group, and 230 healthy subjects were selected as control group. The genotyping of CSPG4P12 rs2880765, rs6496932 and rs8040855 was performed using TaqMan-MGB fluorescent probe labeling method. Odds ratio (OR) and 95% confidence interval (CI) were calculated by unconditional Logistic regression model to analyze the association between polymorphic genetic variation of CSPG4P12 gene and the risk of SCLC. The SCLC DMS114 cells were transfected with pUC-57 plasmid (control group) and CSPG4P12 over-expression plasmid (OV-CSPG4P12 group), respectively. The efficiencies of CSPG4P12 over-expression in two groups were verified by real-time fluorescence quantitative PCR(RT-qPCR) method. Cell counting kit-8 (CCK-8) method was used to detect the cell proliferation activities of cells in two groups. Transwell chamber assay was used to detect the numbers of migration and invasion cells in two groups, respectively. Hoechst 33342 fluorescence staining was used to observe the cell apoptosis in two groups. Results The ArrayExpress database E-GEOD-60052 cohort analysis showed that the expression level of CSPG4P12 mRNA in SCLC tissue was decreased compared with normal tissue (P<0.001). The expression of CSPG4P12 had positive correlations with the immune checkpoint genes including leukocyte associated immunoglobulin like receptor 1 (LAIR1) (r=0.47, P<0.001), tumor necrosis factor(TNF) receptor superfamily member 9 (TNFRSF9) (r=0.38, P<0.01), and TNF superfamily member 9 (TNFSF9) (r=0.44, P<0.001). The ESTIMATE algorithm results showed that the matrix score, immune score and ESTIMATE composite score of the patients in CSPG4P12 low expression group were lower than those in CSPG4P12 high expression group (P<0.01). The CIBERSORT algorithm results showed that compared with CSPG4P12 high expression group, the infiltration of M0 macrophages in CSPG4P12 low expression group was increased (P<0.05) and the infiltration of mast cells resting was decreased (P<0.05). The CSPG4P12 expression level had positive correlations with infiltration of mast cells resting (r=0.35, P=0.03) and mononuclear cell infiltration (r=0.34, P=0.034). In case-control studies, compared with AA genotype, CSPG4P12 rs2880765 AT and TT genotype carriers had a higher risk of SCLC (OR=1.68, 95%CI=1.15-2.45, P<0.01). The stratified analysis showed that genetic variation of rs2880765 A>T increased the risk of SCLC in the male, younger age group(≤60 years) and smoking subgroups (males: OR=1.86, 95%CI=1.18-2.93, P<0.01; ≤60 years: OR=1.73, 95%CI=1.11-2.68, P<0.01; smoking: OR=2.76, 95%CI=1.49-5.13, P=0.001). The cell biology experiment showed that compared with control group, the proliferation abilities of the cells in OV-CSPG4P12 group were significantly decreased at 48 and 72 h (P<0.01), while the number of migration cells at 24 h was significantly decreased (P<0.01), the number of apoptotic cells at 24 h was increased (P<0.05) and the number of invasion cells at 48 h was significantly decreased (P<0.01). Conclusion CSPG4P12 is lowly expressed in SCLC tumor tissue, which is associated with immune infiltration. The genetic variation of CSPG4P12 rs2880765 A>T can increase the risk of SCLC, and its over-expression can inhibit cell proliferation, migration and invasion, and promote apoptosis.

Key words: Chondroitin sulfate proteoglycan 4 pseudogene 12, Immune infiltration, Genetic variation, Cell biological function, Small cell lung cancer

中图分类号: 

  • R734.2